Last edition
News about "Non-Small Cell Lung Cancer "
ArriVent's FURVENT Phase 3 Trial Misses Primary PFS Endpoint
ArriVent’s FURVENT Phase 3 trial of firmonertinib in EGFR exon 20 insertion-mutant NSCLC did not meet its primary PFS endpoint.
Non-Small Cell Lung Cancer | 07/10/2026 | By News Bureau
HUTCHMED, AstraZeneca Submit US NDA for Orpathys-Tagrisso Combination
AstraZeneca submits a US FDA NDA for Orpathys plus Tagrisso in MET-driven NSCLC following EGFR-TKI progression, supported by positive Phase 3 SAFFRON PFS and OS results.
Non-Small Cell Lung Cancer | 01/10/2026 | By News Bureau | 100
Astellas Advances Setidegrasib Into Phase 3 Trial for NSCLC
Astellas has dosed the first patient in a Phase 3 study evaluating setidegrasib against docetaxel in patients with KRAS G12D-mutated NSCLC.
Non-Small Cell Lung Cancer | 25/09/2026 | By News Bureau | 131
US FDA Grants Fast Track Designation to OncoC4's Cesalatamig
US FDA grants Fast Track Designation to OncoC4’s cesalatamig for patients with NSCLC whose disease has progressed following PD-(L)1-targeted immunotherapy and platinum-based chemotherapy.
Non-Small Cell Lung Cancer | 17/09/2026 | By News Bureau
AstraZeneca, Daiichi Sankyo's Enhertu Shows Superior PFS in First-Line HER2-Mutant NSCLC
DESTINY-Lung04 results showed Enhertu delivered a median PFS of 14.3 months versus 8.3 months with pembrolizumab plus chemotherapy in first-line HER2-mutant advanced NSCLC.
Non-Small Cell Lung Cancer | 16/09/2026 | By News Bureau
Genprex has partnered with Roche Diagnostics to validate TROP2 biomarkers for patient selection in non-small cell lung cancer trials, aiming to accelerate precision medicine and improve treatment outcomes.
Non-Small Cell Lung Cancer | 04/08/2026 | By News Bureau
Akeso Doses First Patient in Phase 1b/2 Trial of HER3 ADC for Advanced Lung Cancer
Akeso has dosed the first patient in its Phase 1b/2 AK138D1-201 trial, assessing the HER3-targeted antibody-drug conjugate AK138D1 as monotherapy and in combination with ivonescimab for patients with advanced non-small cell lung cancer.
Non-Small Cell Lung Cancer | 30/07/2026 | By News Bureau | 181
China Grants Priority Review to Leads Biolabs' Opamtistomig for Advanced Neuroendocrine Carcinoma
NMPA accepts biologics license application under expedited review pathway for investigational PD-L1/4-1BB bispecific antibody targeting advanced extrapulmonary neuroendocrine carcinoma after multiple prior therapies.
Non-Small Cell Lung Cancer | 13/07/2026 | By News Bureau | 134
Roche's Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 Lung Cancer Trial
Roche's investigational KRAS G12C inhibitor divarasib demonstrated superior progression-free and overall survival over approved first-generation therapies in the Phase III Krascendo 1 trial, marking a significant advance in the treatment of previously treated KRAS G12C-mutated non-small cell lung cancer.
Non-Small Cell Lung Cancer | 04/07/2026 | By News Bureau | 281
Nuvation Bio's Taletrectinib Advances UK Regulatory Review for ROS1-Positive Lung Cancer
The UK's MHRA has validated the marketing application for Nuvation Bio's taletrectinib, bringing the next-generation ROS1 inhibitor one step closer to approval for patients with advanced ROS1-positive non-small cell lung cancer in the UK.
Non-Small Cell Lung Cancer | 01/07/2026 | By News Bureau | 119
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy